Gynesonics Technology Featured in Five Presentations at 2015 American Association of Gynecologic Laparoscopists Global Congress

Presentation on Early Clinical Response to Sonata™ System Selected as
Best Abstract In New Instrumentation/Technology Category

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, Inc., a women’s health technology company focused on the
development and commercialization of breakthrough products and
procedures designed to transform the treatment of uterine fibroids,
announced today that its Sonata™ System technology platform for the
transcervically delivered incision-free treatment of uterine fibroids
will be featured in five presentations at the 44th
Annual American Association of Gynecologic Laparoscopists (AAGL) Global
Congress to be held November 15-19 at the MGM Grand Conference Center in
Las Vegas. The AAGL is the leading medical association promoting
minimally invasive gynecologic surgery among surgeons, with over 7,000
members representing 110 countries worldwide.

One of the presentations focused on the Sonata System, titled “Early
Clinical Response to Intrauterine Ultrasound-Guided Transcervical
Radiofrequency Ablation” to be presented by Sebastiaan Veersema, M.D.,
Ph.D., has been selected as the winner of the Daniel F. Kott Award for
the Best Abstract on New Instrumentation or Technology. The abstract,
one of 33 accepted for the conference in the New Instrumentation or
Technology category, was acknowledged by the AAGL for “excellent
research in advancing minimally invasive gynecology.”

Of the 50-patient study, Dr. Veersema and his co-authors concluded that
the Sonata System “produced significant clinical benefits including
reduction in menstrual bleeding, within three months in the majority of
patients.”

“The range of presentations accepted by the AAGL Congress regarding the
Sonata platform describes its potential for advancing patient care. It
is also emblematic of the strong clinician interest we are seeing in our
Sonata System, our enhanced, next generation technology platform for the
incision-free treatment of uterine fibroids,” said Gynesonics President
and CEO Christopher M. Owens. “The presentations demonstrate that our
technology is performing well, producing compelling outcomes.”

Topics and Presenters by Day and Time (Pacific
Standard Time):

Tuesday, November 17:
Open Communications 6 – New Instruments
2:15 – 3:15 pm, Room 115

1.

 

Correlation of Reductions in Perfused Fibroid Volume With
Subsequent Reductions in Total Fibroid Volume After Transcervical
Radiofrequency Ablatio
n – Marlies Bongers, M.D., Ph.D., Maxima
Medical Center, Eindhoven, Netherlands

 

2.

Early Clinical Response to Intrauterine Ultrasound-Guided
Transcervical Radiofrequency Ablation
– Sebastiaan Veersema,
M.D., Ph.D., St. Antonius Hospital, Utrecht, Netherlands

 

3.

The SONATA Study: Sonography-Guided Transcervical Ablation of
Uterine Fibroids
– Gretchen Makai, M.D., Christiana Care
Health System, Newark, Delaware

Wednesday, November 18:
Open Communications 21 – New Instruments
3:20-5:00 pm, Room 112/113

4.

 

Longitudinal Course of Fibroid Volume Reduction and Symptom
Relief After Transcervical Radiofrequency Ablation
– Jose
Garza-Leal, M.D., Hospital Universitario “Dr. José Eleuterio
González” de Universidad Autonoma de Nuevo León, Monterrey, Mexico

Virtual Poster: Congress Day 1 and 2, 11:00 am – 5:00 pm

5.  

Normal Pregnancy Outcome after Transcervical Radiofrequency
Ablation of Uterine Fibroids
– Jose Garza-Leal, M.D.

 

About Sonata System

The Sonata™ System, the next generation of Gynesonics’ technology
platform (the previous generation referred to as VizAblate), uses
radiofrequency energy to ablate fibroids under intrauterine sonography
guidance. The Sonata™ System, including the SMART Targeting Guide,
enables the gynecologist to target fibroids and optimize ablations
within them. Sonata™ System’s design provides a straightforward,
transcervical access for a uterus preserving, incision-free fibroid
treatment. This intrauterine approach is designed to avoid the
peritoneal cavity. In October 2014, Gynesonics announced FDA approval of
the SONATA IDE pivotal trial for their latest generation Sonata™ System.

About Gynesonics

Gynesonics is a women’s healthcare company focused on minimally invasive
solutions for symptomatic uterine fibroids. Gynesonics has developed the
Sonata™ System for the transcervical treatment of symptomatic uterine
fibroids under intrauterine sonography guidance. The Sonata™ System is
CE Marked and approved for sale in the European Union. Sonata™ System is
not available for sale in the United States. Gynesonics is a privately
held company with headquarters in Redwood City, CA.

Contacts

Gynesonics
Chris Owens, +1.650.216.3860
President and CEO
www.gynesonics.com